Richard J. Kim - 20 Feb 2024 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Reporting relationship: Chief Commercial Officer
Issuer ticker: AVDL
Reported as of: 20 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2024, 06:28:57 UTC
Prior SEC filing: 05 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Jerad G. Seurer, as Attorney-in-Fact

Key filing fact

Richard J. Kim filed Form 4 for AVADEL PHARMACEUTICALS PLC (AVDL) on 04 Mar 2024.

Key facts

This page summarizes Richard J. Kim's Form 4 filing for AVADEL PHARMACEUTICALS PLC (AVDL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Mar 2024, 06:28.

Change

Previous filing in this sequence was filed on 05 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVDL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +147,000
Change %
Price: $0.000000
Shares after: 147,000
Date: 20 Feb 2024
Ownership: Direct
Underlying class: ADSs
Underlying amount: 147,000
Exercise price: $13.57
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Options become exercisable as to 36,750 ADSs on each of the first four anniversaries after the 2/20/2024 grant date.

Footnote F2

The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.